SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Al-Sharaa denies he called for 80% of Syrians to return from Germany - 2Excited visitors for NASA's moon launch jockey for prime views
- 31,000-mile Saharan dust storm, from the sky and from the ground
- 4Cheetos and Doritos to launch new versions without artificial dyes
- 5As Western heat wave ends, scientists try to make sense of its length and intensity
- Creative Style: 10 Architects Reclassifying the Business
- Manual for 10 Scrumptious Specialty Mixed drinks
- These 3 Nail-Free Finds Completely Transformed My Drab Bathroom
- UN estimates over 2,000 Sudanese pregnant women have fled el-Fasher to escape conflict
- High Court weighs Assenheim appeal over release of Feldstein interview raw footage
- Americans generally like wolves − except when we’re reminded of our politics
- Employers and staff feel effect of fuel price rise
- 'Stranger Things' star debunks claims of 'unseen footage' from Season 5, Volume 2 as backlash intensifies ahead of the series finale
- Looking for a great Thanksgiving side dish recipe? These are the crowd-pleasers the Yahoo team swears by.
